Correlations between changes in cytokines and clinical outcomes for early phase (proof of concept) trials in active diffuse systemic sclerosis using data from an imatinib study-Reference-Cited by-同舟云学术

Correlations between changes in cytokines and clinical outcomes for early phase (proof of concept) trials in active diffuse systemic sclerosis using data from an imatinib study

Published:2014-05-20 Issue:10 Volume:53 Page:1830-1834
ISSN:1462-0324
Container-title:Rheumatology
language:en
Short-container-title:Rheumatology

Author:

Pope J.,Walker K. M.,de Leon F.,Vanderhoek L.,Seney S.,Summers K. L.

Publisher

Oxford University Press (OUP)

Subject

Pharmacology (medical),Rheumatology

Link

http://academic.oup.com/rheumatology/article-pdf/53/10/1830/6897681/keu216.pdf

Reference19 articles.

1. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)

2. Rational therapy in the treatment of systemic sclerosis

3. High-dose versus low-dose ?-penicillamine in early diffuse systemic sclerosis trial: lessons learned

4. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of imatinib mesylate in systemic sclerosis. A systematic review and meta-analysis;Expert Review of Clinical Immunology;2020-09-01

2. Imatinib-loaded gold nanoparticles inhibit proliferation of fibroblasts and macrophages from systemic sclerosis patients and ameliorate experimental bleomycin-induced lung fibrosis;Journal of Controlled Release;2019-09

3. Serum Soluble Vascular Cell Adhesion Molecule-1 Overexpression Is a Disease Marker in Patients with First-Time Diagnosed Antinuclear Antibodies: A Prospective, Observational Pilot Study;BioMed Research International;2018

4. Editorial: Bench to Bedside—and Back Again: Finding the Goldilocks Zone Within the Scleroderma Universe;Arthritis & Rheumatology;2017-12-29

5. Proteomic Analysis of Sera from Individuals with Diffuse Cutaneous Systemic Sclerosis Reveals a Multianalyte Signature Associated with Clinical Improvement during Imatinib Mesylate Treatment;The Journal of Rheumatology;2017-03-15